Literature DB >> 22794697

Chapter 24: Anaphylaxis.

Paul A Greenberger, Anne M Ditto.   

Abstract

Anaphylaxis is a sudden-onset, immediate reaction that implies a risk of death. Think of a "rule of 2's" for anaphylaxis implying that reactions usually begin within 2 minutes to 2 hours after injection, infusion, ingestion, contact, or inhalation. Fatalities can be from asphyxiation from laryngeal or oropharyngeal swelling, collapse from hypotensive shock, cardiac arrest, or acute severe bronchoconstriction causing respiratory failure and arrest. When there is activation of mast cells and basophils in anaphylaxis, chemical mediators are detectable. The preformed mediators from mast cells include histamine, tryptase, carboxypeptidase A, and proteoglycans (heparin and chondroitin sulfates). Newly synthesized mediators include prostaglandin D(2), leukotriene D(4), and platelet-activating factor. Crucial actions of the mediators include an abrupt increase in vascular permeability, vascular smooth muscle relaxation, and bronchial smooth muscle contraction. Anaphylaxis can be classified into immunologic, nonimmunologic, or idiopathic based on the associated mechanism. For example, immunologic causes of anaphylaxis are those mediated by IgE antibodies acting through the FcεR I (foods, insect venom, and beta-lactam antibiotics) whereas non-IgE immunologic anaphylaxis is mediated without presence of antiallergen IgE antibodies or via FcεRI activation (radiographic contrast material). Nonimmunologic anaphylaxis involves mast cell mediator release such as occurs with exercise, cold temperature exposure, or from medications such as opioids or vancomycin. Idiopathic anaphylaxis involves mast cell activation (acutely elevated urine histamine or serum tryptase) and activated lymphocytes. Because anaphylaxis is a medical emergency, the drug of choice is epinephrine, not H(1)-receptor antagonists.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22794697     DOI: 10.2500/aap.2012.33.3557

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  8 in total

Review 1.  Anaphylaxis Conundrum: A Trojan Horse Phenomenon.

Authors:  Ann Esquivel; William W Busse
Journal:  J Allergy Clin Immunol Pract       Date:  2016-10-17

2.  IgE-based Immunotherapy of Cancer -A Comparative Oncology Approach.

Authors:  Josef Singer; Erika Jensen-Jarolim
Journal:  J Carcinog Mutagen       Date:  2014-05-31

3.  MRI reveals edema in larynx (but not in brain) during anaphylactic hypotension in anesthetized rats.

Authors:  Ichiro Toyota; Mamoru Tanida; Toshishige Shibamoto; Mofei Wang; Yasutaka Kurata; Hisao Tonami
Journal:  Allergy Asthma Immunol Res       Date:  2013-09-02       Impact factor: 5.764

4.  Anaphylaxis Imaging: Non-Invasive Measurement of Surface Body Temperature and Physical Activity in Small Animals.

Authors:  Krisztina Manzano-Szalai; Isabella Pali-Schöll; Durga Krishnamurthy; Caroline Stremnitzer; Ingo Flaschberger; Erika Jensen-Jarolim
Journal:  PLoS One       Date:  2016-03-10       Impact factor: 3.240

Review 5.  Epidemiology, Mechanisms, and Diagnosis of Drug-Induced Anaphylaxis.

Authors:  Maria Isabel Montañez; Cristobalina Mayorga; Gador Bogas; Esther Barrionuevo; Ruben Fernandez-Santamaria; Angela Martin-Serrano; Jose Julio Laguna; Maria José Torres; Tahia Diana Fernandez; Inmaculada Doña
Journal:  Front Immunol       Date:  2017-05-29       Impact factor: 7.561

6.  Clinical Manifestations and Causes of Anaphylaxis. Analysis of 382 Cases from the Anaphylaxis Registry in West Pomerania Province in Poland.

Authors:  Iwona Poziomkowska-Gęsicka; Michał Kurek
Journal:  Int J Environ Res Public Health       Date:  2020-04-17       Impact factor: 3.390

Review 7.  Prospects for therapeutic tolerance in humans.

Authors:  Kenneth F Baker; John D Isaacs
Journal:  Curr Opin Rheumatol       Date:  2014-03       Impact factor: 5.006

8.  Proteomic and Biological Analysis of an In Vitro Human Endothelial System in Response to Drug Anaphylaxis.

Authors:  Alma Yuste-Montalvo; Sergio Fernandez-Bravo; Tamara Oliva; Carlos Pastor-Vargas; Diana Betancor; María José Goikoetxea; José Julio Laguna; Juan Antonio López; Gloria Alvarez-Llamas; Javier Cuesta-Herranz; Marta Martin-Lorenzo; Vanesa Esteban
Journal:  Front Immunol       Date:  2021-06-25       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.